Fluidigm Corp Del (NASDAQ:FLDM)

• The turnaround for this San Francisco company will likely take place in the 2. half of 2017 - with a Mkt.Cap of 200m$ & rev. of 100m$ a year in a high-margin business, there's a lot of upside potential.

• Fluidigm is maturing - financially disciplined, refocused attention on core rev. for the future & currently streamlining internal communications, team-structures & work-flow.

• Early adopters of "CyTOF" -like univ. researchers- have leveraged this technology in single cell analysis to obtain results previously not possible, & CyTOF is seeing more-&-m. positive attention & interest in the life-sciences (just google "CyTOF").

• CyTOF was first developed between the Univ. of Toronto & DVS Sciences Inc. which Fluidigm acquired in 2014 & further developed (https://en.m.wikipedia.org/wiki/Mass_cytometry).

• May 2017 conf. call (https://seekingalpha.com/article/4069444-fluidigm-corps-fldm-ceo-stephen-linthwaite-q1-2017-results-earnings-call-transcript).

• Institutional ownership is at ~100% (http://www.nasdaq.com/symbol/fldm/institutional-holdings)
... for a company this small, there is obviously significant risk & you should do your own research & only invest in what you understand... with that being said - if you were ever looking for an "early company" before they were discovered & their potential realized by the broader market (and not just their customers), then you should take a look at Fluidigm.

• Insider shares traded have also been relatively healthy
(http://www.nasdaq.com/symbol/fldm/insider-trades)

• Universities & research-institutions adopting Fluidigm's tech. are also likely to invest in the company.

• But you should only invest in something you understand - Googling "Fluidigm", "CyTOF" or "Mass Cytometry" is a good place to start...

Little understanding of the bio tools space undervalues this stock.